preclinical models comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-19. Numbers and descriptions here follow the published literature rather than marketing material.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
=== Etymology === The name estrogen is derived from the Greek οἶστρος (oîstros), literally meaning "verve" or "inspiration" but figuratively sexual passion or desire, and the suffix -gen, meaning "producer of".
In either case, a mixture of unbound ligands, proteins, ligand-protein complexes is passed through a column of porous beads. Ligand-protein complexes are excluded from entering the beads and exit the column quickly, while unbound ligands must travel through the beads and are retained by the column for a longer time. Ligands that elute from the column early on are therefore inferred to be bound to a protein. The automated ligand identification system (ALIS), developed by Schering-Plough, uses a combined HPLC-based SEC to liquid chromatography-mass spectrometry (LC-MS) system that separates ligand-protein complexes from unbound ligands using SEC and diverts the complex toward an LC-MS system for on-line analysis of bound ligands. Novartis' SpeedScreen uses SEC in 96-well spin column format, also known as gel filtration chromatography, which allows for simultaneous removal of unbound ligands from up to 96 samples. Samples are also passed through porous beads, but centrifugation is used to move the sample through the column. SpeedScreen is not coupled to an LC-MS system and requires further processing prior to final analysis. In this case, ligands must be freed from their targets and analyzed separately.
An ion trap mass spectrometer may incorporate a Penning trap (Fourier-transform ion cyclotron resonance), Paul trap or the Kingdon trap. The Orbitrap, introduced in 2005, is based on the Kingdon trap. Other types of mass spectrometers may also use a linear quadrupole ion trap as a selective mass filter.
Heart failure - Giving 2.5 times of previous oral dose twice daily for those with acute decompensated heart failure is a reasonable strategy. However, daily assessment of clinical response is needed to adjust the subsequent doses. Edema - Volume overload associated with liver cirrhosis, heart failure, or nephrotic syndrome Cerebral edema - intravenous furosemide can be combined with mannitol to initiate rapid diuresis. However, the optimum duration of such treatment remains unknown. Frequent fluid status monitoring is required to prevent intravascular volume depletion which leads to reduced cerebral perfusion. A bolus intravenous dose of 10 or 20 mg of furosemide can be administered and then followed by intravenous bolus of 2 or 3% hypertonic saline to increase the serum sodium level. Pulmonary edema - Slow intravenous bolus dose of 40 to 80 mg furosemide at 4 mg per minute is indicated for patients with fluid overload and pulmonary edema. Such dose can be repeated after 20 minutes. After the bolus, a continuous intravenous infusion can be given at 5 to 10 mg per hour. For those with underlying renal impairment or severe heart failure, up to 160 to 200 mg bolus dose can be given. Hypertension - A systematic review by the Cochrane Hypertension group assessing the anti-hypertensive effects of loop diuretics found only a modest reduction in blood pressure when compared to placebo. According to Joint National Committee (JNC-8) guidelines, the first line treatment of hypertension is thiazide diuretics. The use of loop diuretics is not mentioned in this guideline.
Artistic Achievement – Lumino City Audio Achievement – Alien: Isolation Best Game – Destiny British Game – Monument Valley Debut Game – Never Alone Family – Minecraft: Console Editions Game Design – Middle-earth: Shadow of Mordor Game Innovation – The Vanishing of Ethan Carter Mobile & Handheld – Monument Valley Online Multiplayer – Hearthstone: Heroes of Warcraft Original Music – Far Cry 4 Original Property – Valiant Hearts: The Great War Performer – Ashley Johnson (as Ellie, The Last of Us: Left Behind) Persistent Game – League of Legends Sports – OlliOlli Story – The Last of Us: Left Behind BAFTA Ones to Watch Award – Chambara Academy Fellowship – David Braben
Sources: en.wikipedia.org
=== Enzymes === Enzymes are involved in internal processes within mast cells including signaling pathways for mast cell activation and other mechanisms regulating cellular functions. They can include:
Protolichesterinic acid is a naturally occurring γ-lactone compound found in various lichen species. Its structure consists of a combination of a lactone ring with a carboxylic acid group and a long aliphatic side chain. First isolated in the early 20th century, protolichesterinic acid has drawn scientific interest due to its diverse biological activities, including antimicrobial, antifungal, and anti-inflammatory properties. It is also noted for its potential as a therapeutic agent, particularly as a selective inhibitor of the 5-lipoxygenase enzyme, which is implicated in inflammatory diseases. Protolichesterinic acid is typically extracted from lichens such as Cetraria islandica using advanced chromatographic techniques and has been studied for its role in both natural product chemistry and pharmacology.
== Applications == With an expanded genetic code, the unnatural amino acid can be genetically directed to any chosen site in the protein of interest. The high efficiency and fidelity of this process allows a better control of the placement of the modification compared to modifying the protein post-translationally, which, in general, will target all amino acids of the same type, such as the thiol group of cysteine and the amino group of lysine. Also, an expanded genetic code allows modifications to be carried out in vivo. The ability to site-specifically direct lab-synthesized chemical moieties into proteins allows many types of studies that would otherwise be extremely difficult, such as:
== Oxford == Heseltine campaigned briefly as a volunteer in the October 1951 general election before going up to Pembroke College, Oxford. While there, in frustration at his inability to be elected to the committee of the Oxford University Conservative Association, he founded the breakaway Blue Ribbon Club. Along with undergraduates Guy Arnold, Julian Critchley and Martin Morton he canvassed workers at the gates of the Vickers Shipyard in Barrow-in-Furness. Julian Critchley recounted a story from his student days of how he plotted his future on the back of an envelope, a future that would culminate as prime minister in the 1990s. A more detailed apocryphal version has him writing down: 'millionaire 25, cabinet member 35, party leader 45, prime minister 55,' though Heseltine himself disputes this and instead recalls a lack of self-belief. He became a millionaire and was a member of the Cabinet from the age of 46, but narrowly failed to become Party Leader or prime minister. His biographers Michael Crick and Julian Critchley (who was a contemporary of Heseltine's at Brockhurst Prep School) recount how, despite not having an innate gift for public speaking, he became a strong orator through much effort, which included practising his speeches in front of a mirror, listening to tape recordings of speeches by television administrator Charles Hill, and taking voice-coaching lessons from a vicar's wife.
After hypothyroidism was found to cause a lower basal metabolic rate, this was used as a marker to guide adjustments in therapy in the early 20th century (around 1915). However, a low basal metabolic rate was known to be non-specific, also present in malnutrition. The first laboratory test to help assess thyroid status was the serum protein-bound iodine, which came into use around the 1950s. In 1971, the thyroid stimulating hormone (TSH) radioimmunoassay was developed, which was the most specific marker for assessing thyroid status in patients. Many people who were being treated based on basal metabolic rate, minimizing hypothyroid symptoms, or based on serum protein-bound iodine, were found to have excessive thyroid hormone. The following year, in 1972, a T3 radioimmunoassay was developed, and in 1974, a T4 radioimmunoassay was developed.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.